Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Almitrine is a diphenylmethylpiperazine derivative classified as a respiratory stimulant. It acts primarily as an agonist of peripheral chemoreceptors located on the carotid bodies, enhancing respiration by increasing arterial oxygen tension and decreasing arterial carbon dioxide tension. Almitrine is used in the treatment of chronic obstructive pulmonary disease (COPD) and has also been reported to be beneficial for nocturnal oxygen desaturation without impairing sleep quality. In some markets, it has been combined with raubasine (as Duxil) for age-related cerebral disorders and functional rehabilitation after stroke. The drug may also have anti-oxidant effects related to its action on the mitochondrial electron transport chain[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on almitrine.